Skip To Content

Study ID: Genentech ML28897/PRO 02 MY PATHWAY

Title:

MY PATHWAY: AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB, AND VISMODEGIB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS

Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Steven Powell, MD,Anu Gaba, MD
Disease:
Other
Stage:
Phase IIA
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.